Programmed Cell Death 1 Receptor

"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.

Descriptor ID	D061026
MeSH Number(s)	D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
Concept/Terms	Programmed Cell Death 1 Receptor Programmed Cell Death 1 Receptor PD-1 Receptor PD 1 Receptor Receptor, PD-1 CD279 Antigen Antigen, CD279 PD1 Receptor Receptor, PD1 Programmed Cell Death 1 Protein Antigens, CD279 CD279 Antigens

Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
Programmed Cell Death 1 Receptor [D23.101.100.894.790]

Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.

Bar chart showing 31 publications over 12 distinct years, with a maximum of 6 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2009	0	1	1
2012	0	1	1
2013	0	1	1
2014	0	1	1
2016	1	1	2
2017	2	1	3
2018	5	1	6
2019	1	4	5
2020	0	2	2
2021	3	2	5
2022	0	3	3

Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.

Howell AV, Gebregziabher M, Thiers BH, Graboyes EM, Paulos CM, Wrangle JM, Hunt KJ, Wallace K. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. J Geriatr Oncol. 2022 Sep; 13(7):1003-1010.

View in: PubMed
Wei J, Zhang J, Wang D, Cen B, Lang JD, DuBois RN. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas. Cancer Prev Res (Phila). 2022 05 03; 15(5):285-296.

View in: PubMed
In GK, Nallagangula A, Choi JS, Tachiki L, Blackburn MJ, Capone S, Bollin KB, Reuben DY, Shirai K, Zhang-Nunes S, Ragab O, Terando A, Hu JC, Lee H, Bhatia S, Chandra S, Lutzky J, Gibney GT. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer. 2022 05; 10(5).

View in: PubMed
Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.

View in: PubMed
Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.

View in: PubMed
Dryja P, Fisher C, Woster PM, Bartee E. Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.

View in: PubMed
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. Cancer Immunol Res. 2021 05; 9(5):568-582.

View in: PubMed
Keilson JM, Knochelmann HM, Paulos CM, Kudchadkar RR, Lowe MC. The evolving landscape of immunotherapy in solid tumors. J Surg Oncol. 2021 Mar; 123(3):798-806.

View in: PubMed
Sun F, Guo ZS, Gregory AD, Shapiro SD, Xiao G, Qu Z. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer. 2020 05; 8(1).

View in: PubMed
Watanabe Y, Yamaguchi Y, Takamura N, Takahashi Y, Aihara M. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab. Eur J Cancer. 2020 05; 131:1-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals